Stifel analyst Benjamin Burnett initiated coverage of Disc Medicine with a Buy rating and $37 price target. The firm believes lead asset, bitopertin, will sufficiently lower PPIX levels and increase sunlight sensitivity in Erythropoietic Protoporphyria, or EPP, patients and that initial data due in Q2 will be "well received."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on IRON:
- Disc Medicine to Participate in H.C. Wainwright BioConnect Investor Conference
- 3 Best Stocks to Buy Now, 4/20/2023, According to Top Analysts
- Disc Medicine initiated with an Overweight at Morgan Stanley
- Disc Medicine to Host Disease Webinar with KOLs on Erythropoietic Protoporphyria (EPP)
- Disc Medicine expects cash to fund operational plans into 2025
